Libros sobre el tema "Cancer drug resistance, tumor metabolism"

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Cancer drug resistance, tumor metabolism.

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 25 mejores mejores libros para su investigación sobre el tema "Cancer drug resistance, tumor metabolism".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore libros sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Dr, Mehta Kapil y Siddik Zahid H, eds. Drug resistance in cancer cells. New York, NY: Springer, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Benjamin, Bonavida, ed. Sensitization of cancer cells for chemo/immuno/radio-therapy. Totowa, NJ: Humana Press, 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

S, El-Deiry Wafik, ed. Tumor progression and therapeutic resistance. New York, NY: New York Academy of Sciences, 2005.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

B, Roninson Igor, ed. Molecular and cellular biology of multidrug resistance in tumor cells. New York: Plenum Press, 1991.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Lauricella, Marianna y Sonia Emanuele. Novel apoptotic drugs in targeting tumor cells. Trivandrum, Kerala, India: Researh Signpost, 2007.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Kim, Kŏn-hong. Yubangam ŭi taje yangmul naesŏng saengchʻe chipʻyo palgul mit kŭ yuyongsŏng kŏmjŭng =: Identification of biomarkers for multidrug resistance and validation of markers in breast cancer tissue. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Bonavida, Benjamin. Chemo-immunosensitization of resistant tumor cells to cell death by apoptosis, 2006. Trivandrum: Transworld Research Network, 2006.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Julia, Gee, Nicholson Robert I y SpringerLink (Online service), eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Dordrecht: Springer Netherlands, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

1940-, Tabuchi K., ed. Biological aspects of brain tumors: Proceedings of the 8th Nikko Brain Tumor Conference, Karatsu (Saga) 1990. Tokyo: Springer-Verlag, 1991.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Gregory, Bock, Goode Jamie, Novartis Foundation y Symposium on Mechanisms of Drug Resistance in Epilepsy : Lessons from Oncology (2001 : London, England), eds. Mechanisms of drug resistance in epilepsy: Lessons from oncology. Chichester, England: Wiley, 2002.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Bates, Susan E., Kapil Mehta y Zahid H. Siddik. Drug Resistance in Cancer Cells. Springer, 2010.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

Bonavida, Benjamin. Sensitization of Cancer Cells for Chemo/Immuno/Radio-Therapy. Humana Press, 2010.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Molecular Mechanisms Of Tumor Cell Resistance To Chemotherapy Targeted Therapies To Reverse Resistance. Springer-Verlag New York Inc., 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Gonzalez-Perez, Ruben R. y Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Gonzalez-Perez, Ruben R. y Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Gonzalez-Perez, Ruben R. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

Gonzalez-Perez, Ruben R. y Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

Pacak, Karel y INTERNATIONAL SYMPOSIUM ON CATECHOLAMINE. Tumor Progression and Therapeutic Resistance (TPR) (Annals of the New York Academy of Sciences). New York Academy of Sciences, 2006.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

Hiscox, Stephen, Julia Gee y Robert I. Nicholson. Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Hiscox Stephen Gee Julia Nicholson Robert I, 2010.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

Biological aspects of brain tumors: Proceedings of the 8th Nikko Brain Tumor Conference, Karatsu (Saga) 1990. Springer-Verlag, 1991.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

Multidrug resistance in cancer cells: Molecular, biochemical, physiological, and biological aspects. Chichester: J. Wiley, 1996.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

(Editor), Sudhir Gupta y Takashi Tsuruo (Editor), eds. Multidrug Resistance in Cancer Cells: Molecular, Biochemical, Physiological and Biological Aspects. Wiley, 1996.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Tsuruo, Takashi y Sudhir Gupta. Multidrug Resistance in Cancer Cells: Molecular, Biochemical, Physiological and Biological Aspects. Wiley & Sons, Incorporated, John, 2007.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Texto completo
Resumen
The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

Josephs, Debra H., Heather J. Bax, Giulia Pellizzari, James F. Spicer, Ana Montes y Sophia N. Karagiannis. Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0001.

Texto completo
Resumen
Despite improvements over the past decade in the treatment of ovarian cancer, many patients are at risk of recurrent disease and emerging drug resistance. The increased selectivity and reduced toxicity of molecularly targeted anti-cancer agents renders them attractive for development in ovarian cancer, and monoclonal antibodies targeting ovarian cancer-specific tumor antigens represent the largest such group investigated in this clinical setting. This chapter describes examples of monoclonal antibodies clinically evaluated for efficacy in ovarian cancer. These agents recognize molecular targets expressed on tumors or within tumor microenvironments that may be essential for tumor cell survival and proliferation. Recently, antibodies targeting checkpoint molecules on immune cells have shown efficacy in modulating anti-tumor immunity, and applications in ovarian carcinomas are evaluated. The chapter focuses on therapeutic agents’ attributes on targeting key cancer growth and progression pathways, and propensity to engender effector functions by activating immune effector cells in tumors and the circulation.
Los estilos APA, Harvard, Vancouver, ISO, etc.
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía